Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

Cystic Fibrosis Clinical Trial

Official title:

A Blinded, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam for Inhalation (AI) in Cystic Fibrosis Patient With Lung Disease Due to P. Aeruginosa Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01055847
• Other study ID #: CP-AI-003
• Status: Completed
• Phase: Phase 2
• First received: January 23, 2010
• Last updated: January 25, 2010
• Start date: June 2003
• Est. completion date: September 2004

Study information

• Verified date: January 2010
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is multicenter placebo-controlled study evaluating the safety and efficacy of AI at two dosage levels compared to placebo in CF patients with P. aeruginosa lung infection.

Description:

This is multicenter placebo-controlled study evaluating the safety and efficacy of a 14-day treatment of AI at two dosage levels as compared to placebo, given twice daily, in CF patients with P. aeruginosa lung infection, delivered by the eFlow investigational nebulizer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 105
• Est. completion date: September 2004
• Est. primary completion date: August 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent prior to the performance of any study related procedures.

• 13 years of age and above.

• Documented sweat chloride = 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) or homozygosity for ?F508 genetic mutation or heterozygosity for two well characterized mutations.

• Ability to perform pulmonary function tests.

• FEV1 = 40% predicted at Visit 1 (Screening).

• SaO2 = 90% at Visit 1 (Screening).

• P. aeruginosa present in sputum at Visit 1 (Screening).

• Ability to expectorate sputum on a daily basis.

Exclusion Criteria:

• Administration of any antibiotic with antipseudomonal activity by any route within 56 days prior to Visit 1 (Screening).

• Administration of any investigational drug or device within 28 days of Visit 1 (Screening) and within 6 half-lives of the investigational drug.

• Oral corticosteroids in doses exceeding 10 mg per day or 20 mg every other day.

• History of sputum culture or throat swab culture yielding B. cepacia in the previous two years.

• Current daily continuous oxygen supplementation or requirement for more than 2 L/min at night.

• Known local or systemic hypersensitivity to monobactam antibiotics.

• Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid medications within 7 days prior to Visit 1 (Screening).

• Changes in physiotherapy technique or schedule within 7 days prior to Visit 1 (Screening).

• History of lung transplantation.

• A chest radiograph at Visit 1 (Screening) or within the previous 90 days of Screening, with abnormalities indicating a significant acute finding (eg, lobar infiltrate and atelectasis, pneumothorax, or pleural effusion).

• Abnormal renal or hepatic function or serum chemistry at Visit 1 (Screening):

• AST, ALT > 2.5 times upper limit of normal range.

• Creatinine > 1.5 times upper limit of normal range.

• Positive pregnancy test. All women of childbearing potential will be tested.

• Female of childbearing potential who is lactating or is not practicing acceptable method of birth control (eg, hormonal or barrier methods, or IUD).

• Findings at Visit 1 (Screening) that, in the investigator's opinion, would compromise the safety of the patient or the quality of the study data.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• CF
• Communicable Diseases
• Cystic Fibrosis
• Fibrosis
• Infection
• Lung Infection
• Pseudomonas Aeruginosa
• Pseudomonas Infections

Intervention

Drug:
• Aztreonam for Inhalation (AI)
Aztreonam for Inhalation
• Placebo
Saline Placebo

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Gilead Sciences	Salus Pharma, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in FEV1 from Baseline to Day 14		14 Days	No